

## Belgium firm expands clinical platform to APAC

13 July 2018 | News | By Manbeena Chawla

**The expansion includes the execution of agreements with the National Taiwan University (NTU) to carry out two multi-country, multi-centre studies in multi-ethnic Asian participants.**



Belgium-based cancer diagnostics firm Volition has expanded the clinical trial programme of its Nu.Q platform, being developed to detect colorectal cancer, to the Asia Pacific Region.

The expansion includes the execution of agreements with the National Taiwan University (NTU) to carry out two multi-country, multi-centre studies in multi-ethnic Asian participants.

Nu.Q is designed as a series of simple, cost-effective and accurate blood tests which analyse samples for the presence of early nucleosome markers of cancer. This is intended to facilitate early diagnosis and treatment.

The two trials being performed at the university, will involve 5,000 asymptomatic and 2,000 symptomatic colorectal cancer patients, respectively. Their main objective is to validate the capability of Nu.Q to detect and diagnose colorectal cancer, for marketing purposes.

Recently, Volition also executed an agreement with the National University of Singapore to conduct a 719-subject trial.